Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tangwen Tai
- Development stage
- Phase 3
- Lead developer
- Peking Union Medical College Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Tangwen Tai is a probiotic combination product containing three specific bacterial strains: *Lactobacillus plantarum* LP45, *Lactobacillus acidophilus* La28, and *Bifidobacterium animalis* subsp. *lactis* BAL531. It is currently being evaluated in Phase 3 clinical trials by Peking Union Medical College Hospital for the treatment of polycystic ovary syndrome (PCOS). The product is designed to address gut microbiota dysbiosis, which is hypothesized to play a significant role in the pathogenesis of PCOS by influencing metabolic and hormonal balance. By restoring microbial diversity and correcting taxonomic imbalances in the gastrointestinal tract, Tangwen Tai aims to improve metabolic parameters, immune function, and clinical symptoms in women with PCOS.
- Brand names
- Tangwen Tai
- Other names
- LP45 + La28 + BAL531Probiotic Agent
Beyond the preview
Go deeper on Tangwen Tai.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tangwen Tai.